Durable bleed protection for all bleeding subtypes and favorable safety over 5 years (end-of-study) in the phase 3 HOPE-B trial for persons with severe or moderately severe haemophilia B

Feb 6, 202609:06 am - 9:15 AM
The Auditorium

Presenter: